Patents by Inventor Pierre Beauparlant

Pierre Beauparlant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
    Patent number: 8211912
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: July 3, 2012
    Assignee: Gemin X Pharmaceuticals Canada
    Inventors: Anne Roulston, Pierre Beauparlant
  • Compositions and methods for effecting NADlevels using a nicotinamide phosphoribosyl transferase inhibitor
    Patent number: 8173677
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a patient diagnosed with or suspected to have chronic lymphocytic leukemia (CLL); decreasing cellular NAD+ biosynthesis in a patient diagnosed with or suspected to have CLL; or sensitizing a patient diagnosed with or suspected to have CLL to a DNA damaging therapy. The invention relates to methods for treating a patient diagnosed with or suspected to have CLL.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: May 8, 2012
    Assignee: Gemin X Pharmaceuticals Canada Inc.
    Inventors: Anne Roulston, Pierre Beauparlant
  • COMPOSITIONS AND METHODS FOR EFFECTING NAD+ LEVELS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR
    Publication number: 20090215823
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a patient diagnosed with or suspected to have chronic lymphocytic leukemia (CLL); decreasing cellular NAD+ biosynthesis in a patient diagnosed with or suspected to have CLL; or sensitizing a patient diagnosed with or suspected to have CLL to a DNA damaging therapy. The invention relates to methods for treating a patient diagnosed with or suspected to have CLL.
    Type: Application
    Filed: March 25, 2009
    Publication date: August 27, 2009
    Inventors: Anne Roulston, Pierre Beauparlant
  • Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor
    Publication number: 20090162454
    Abstract: The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.
    Type: Application
    Filed: September 25, 2008
    Publication date: June 25, 2009
    Inventors: Anne Roulston, Pierre Beauparlant
  • Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
    Patent number: 7217844
    Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: May 15, 2007
    Assignee: Gemin X Biotechnologies
    Inventors: Pierre Beauparlant, Giorgio Attardo, Zhiying Zhang, Angela M. Stafford, Rosa Ubillas, James B. McAlpine, Jean-Francois Lavallee, Samuel Fortin, Sasmita Tripathy
  • Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
    Publication number: 20050070540
    Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.
    Type: Application
    Filed: December 1, 2003
    Publication date: March 31, 2005
    Inventors: Pierre Beauparlant, Giorgio Attardo, Zhiying Zhang, Angela Stafford, Rosa Ubillas, James McAlpine, Jean-Francois Lavallee, Samuel Fortin, Sasmita Tripathy